Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

MarketScreener Homepage  >  Equities  >  Australian Stock Exchange  >  Ansell Limited    ANN   AU000000ANN9

ANSELL LIMITED

(ANN)
  Report
SummaryChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryAll NewsPress ReleasesOfficial PublicationsSector newsMarketScreener Strategies

Ansell Limited : On the front line

share with twitter share with LinkedIn share with facebook
05/28/2020 | 08:08am EDT

Formerly a subsidiary of Dunlop, Ansell is an Australian manufacturer of protective gear — such as gloves, masks, aprons and coveralls — for industrial and medical applications.

The company was well-known as a condom manufacturer — it owned the premium brand Skyn — but chose to divest this business in 2017, as industry-wide overcapacity and slowing growth across emerging markets depressed earnings with no recovery in sight.

zb_graphique_de_cours



To management's credit, the USD $520mil sale of the condom business to a Chinese consortium came at the upper end of analysts' expectations. It enabled Ansell to pursue its transformation towards the personal protection business for healthcare, life sciences and industrial workers.

The latter required a series of acquisitions to build up a comprehensive portfolio, with $1.1bn spent on external growth over the 2010-2019 period. Divestments funded half of that amount, fresh equity — $359mil at about $30 per share six years ago — and debt issues the other half.

Total return on investment remains modest, but that isn't management's fault. In effect, the protective gear industry is saturated and commoditized, with no barriers to entry as well as market share gains primarily driven by pricing. There characteristics put a ceiling on organic growth prospects and achievable margins.

Still, the portfolio revamp coupled with an extensive restructuring of manufacturing operations improved operating margins by ~150-200bps, "unusual" costs included. Ansell optimized its footprint and closed three plants — in Mexico and South Korea — while upgrading existing facilities in Vietnam, Malaysia, Sri Lanka and Bangkok.

As in every commodity business, survival rests upon counting among the lowest cost operators. The manufacturing base is undemanding in terms of investments — with capital expenditures of ~$50-60mil against cash from operations of ~$180-220mil — but pricey acquisitions are necessary to achieve growth. Going forward, management made no mystery of their intention to complete at least one buyout per year.

Solid financial standing should support these efforts. Total liabilities of $966mil are almost fully covered by current assets, of which $397mil in cash. Balance sheet strength provides substantial investment flexibility, with $1.2bn in M&A capacity and interest expense ($19mil) covered x12 by operating earnings before depreciation and amortization ($237mil).

Following its streak of acquisitions, the company has redirected cash-flows towards returns of capital to shareholders. Distribution of dividends increased from $50mil in 2013 to $62mil in 2019. Share buybacks reached $364mil over the last four years, as the stock traded at about x16-x18 EPS. The fact that management favored buybacks over distributions suggests that they expect earnings growth above industry averages over the next decade. Analysts think likewise.

Speaking of management, the team that took over in 2005 and restructured the company — which had been weakened by many years of underinvestment at Dunlop — is retiring. Chairman Glenn Barnes has already departed, and CEO Magnus Nicolin should pass the baton before next year.  The duo leaves a solid foundation to the new leadership, who steps in as a dramatic economic downturn is unfolding.

Nevertheless, Ansell's business should prove relatively immune to the crisis, at least within the healthcare segment — roughly half of consolidated revenue — for the company obviously stands on the front lines of combating the spread of COVID-19. It is currently booking record orders for gloves, masks and other protective gears, and that trend shouldn't abate any time soon.

These events also came as it was delivering solid results, propped up by a balanced portfolio, solid momentum in the industrial business, as well as a strong U.S. dollar — although Australian, the company invoices its clients and reports its results in the American currency.

These developments have led analysts — whose consensus is surveyed in real time by MarketScreener — to raise their ratings and estimates, even with the stock trading at x19 forward earnings . The latter has been added to the Europa One fund that Surperformance — MarketScreener's editor and parent company — advises on an exclusive basis.

Stocks mentioned in the article
ChangeLast1st jan.
AMP LIMITED -8.20% 1.4 End-of-day quote.-26.89%
ANSELL LIMITED -2.27% 35.8 End-of-day quote.23.32%
EURO / US DOLLAR (EUR/USD) 0.03% 1.1845 Delayed Quote.5.66%
TEAM, INC. 2.69% 6.5 Delayed Quote.-59.30%
THE NEW HOME COMPANY INC. -2.51% 3.89 Delayed Quote.-16.52%

share with twitter share with LinkedIn share with facebook
All news about ANSELL LIMITED
08/31ANSELL LIMITED : Ex-dividend day for final dividend
FA
08/24Australian shares hit 5-1/2-month high on coronavirus treatment bets
RE
02/24ANSELL LIMITED : Ex-dividend day for interim dividend
FA
2019ANSELL LIMITED : Ex-dividend day for final dividend
FA
2019ANSELL LIMITED : Ex-dividend day for interim dividend
FA
2019ANSELL LIMITED : half-yearly earnings release
2018ANSELL : Healthcare products llc to acquire exam & specialty glove supplier digi..
PU
2018ANSELL LIMITED : Ex-dividend day for final dividend
FA
2018ANSELL LIMITED : Ex-dividend day for interim dividend
FA
2017ANSELL : Announces the closing of the sale of its sexual wellness business
PU
More news
Notations Surperformance©
  Help  
Fundamental ratings
Overall rating
Trading Rating
Investor Rating
Growth (Revenue)
Valuation
Finances
Profitability
Earnings quality
Business Predictability
P/E ratio
Potential
Yield
Consensus
7 days EPS revision
4 months EPS revision
1 year EPS revision
4 months Revenue revision
1 year Revenue revision
Technical ratings
Short Term Timing
Middle Term Timing
Long Term Timing
RSI
Bollinger Spread
Unusual Volumes
Key data
Capitalization (AUD)
4 601 278 879
Capitalization (USD)
3 365 968 456
Net sales (USD)
1 613 700 000
Number of employees
13 513
Sales / Employee (USD)
119 418
Free-Float
99,5%
Free-Float capitalization (AUD)
4 578 849 781
Free-Float capitalization (USD)
3 349 560 923
Avg. Exchange 20 sessions (USD)
25 108 616
Average Daily Capital Traded
0,55%
Income Statement Evolution
EPS & Dividend
EPS Revisions
Revenue Revisions
Consensus
Sell
Buy
Mean consensus HOLD
Number of Analysts 11
Average target price 27,32 $
Last Close Price 26,08 $
Spread / Highest target 21,5%
Spread / Average Target 4,77%
Spread / Lowest Target -13,4%
Consensus revision (last 18 months)